首页> 外文期刊>Journal of Inborn Errors of Metabolism & Screening >Clinical Trials in Mitochondrial Disease An Update on EPI-743 and RP103
【24h】

Clinical Trials in Mitochondrial Disease An Update on EPI-743 and RP103

机译:线粒体疾病的临床试验EPI-743和RP103的更新

获取原文
           

摘要

Mitochondrial dysfunction results in the production of an abnormally high amount of reactive oxygen and nitrogen species, which results in redox imbalance and glutathione deficiency. Therapeutics such as EPI-743 (???±-tocotrienol quinone) and RP103 (cysteamine bitartrate) have the theoretical potential to improve redox imbalance by increasing intracellular glutathione and are currently under investigation in multiple clinical trials. This review provides an update on the use of these compounds in clinical trials related to primary and secondary mitochondrial disorders. These clinical trials have not only provided hope to affected patients and their families and caregivers, but also will serve as important stepping stones for further studies as our understanding of mitochondrial disease pathogenesis continues to improve.
机译:线粒体功能障碍导致产生异常大量的活性氧和氮,这导致氧化还原失衡和谷胱甘肽缺乏。 EPI-743(β-生育三烯酚醌)和RP103(酒石酸半胱氨酸)等治疗剂具有通过增加细胞内谷胱甘肽来改善氧化还原失衡的理论潜力,目前正在多项临床试验中进行研究。这篇综述提供了有关这些化合物在与原发性和继发性线粒体疾病有关的临床试验中的最新使用信息。这些临床试验不仅为受影响的患者及其家人和护理人员提供了希望,而且随着我们对线粒体疾病发病机理的认识不断提高,它们还将成为进一步研究的重要踏脚石。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号